Gene-Gene/NN
Interaction/NN
Analysis/NN
for/IN
the/DT
Accelerated/JJ
Failure/NN
Time/NN
Model/NN
Using/VBG
a/DT
Unified/JJ
Model-Based/JJ
Multifactor/JJ
Dimensionality/NN
Reduction/NN
Method/NN
./.
====================
Although/IN
a/DT
large/JJ
number/NN
of/IN
genetic/JJ
variants/NNS
have/VBP
been/VBN
identified/VBN
to/TO
be/VB
associated/VBN
with/IN
common/JJ
diseases/NNS
through/IN
genome-wide/NN
association/NN
studies/NNS
,/,
there/EX
still/RB
exits/VBZ
limitations/NNS
in/IN
explaining/VBG
the/DT
missing/JJ
heritability/NN
./.
====================
One/CD
approach/NN
to/TO
solving/JJ
this/DT
missing/JJ
heritability/NN
problem/NN
is/VBZ
to/TO
investigate/VB
gene-gene/NN
interactions/NNS
,/,
rather/RB
than/IN
a/DT
single-locus/JJ
approach/NN
./.
====================
For/IN
gene-gene/NN
interaction/NN
analysis/NN
,/,
the/DT
multifactor/JJ
dimensionality/NN
reduction/NN
(/(
MDR/NN
)/)
method/NN
has/VBZ
been/VBN
widely/RB
applied/VBN
,/,
since/IN
the/DT
constructive/JJ
induction/NN
algorithm/NN
of/IN
MDR/NN
efficiently/RB
reduces/VBZ
high-order/JJR
dimensions/NNS
into/IN
one/CD
dimension/NN
by/IN
classifying/VBG
multi-level/JJ
genotypes/NNS
into/IN
high-/JJ
and/CC
low-risk/JJ
groups/NNS
./.
====================
The/DT
MDR/NN
method/NN
has/VBZ
been/VBN
extended/VBN
to/TO
various/JJ
phenotypes/NNS
and/CC
has/VBZ
been/VBN
improved/VBN
to/TO
provide/VB
a/DT
significance/NN
test/NN
for/IN
gene-gene/NN
interactions/NNS
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
propose/VBP
a/DT
simple/JJ
method/NN
,/,
called/VBN
accelerated/VBN
failure/NN
time/NN
(/(
AFT/NN
)/)
UM-MDR/NN
,/,
in/IN
which/WDT
the/DT
idea/NN
of/IN
a/DT
unified/JJ
model-based/VBN
MDR/NN
is/VBZ
extended/VBN
to/TO
the/DT
survival/NN
phenotype/NN
by/IN
incorporating/VBG
AFT-MDR/NN
into/IN
the/DT
classification/NN
step/NN
./.
====================
The/DT
proposed/JJ
AFT/NN
UM-MDR/NN
method/NN
is/VBZ
compared/VBN
with/IN
AFT-MDR/NN
through/IN
simulation/JJ
studies/NNS
,/,
and/CC
a/DT
short/JJ
discussion/NN
is/VBZ
given/VBN
./.
====================
For/IN
the/DT
past/JJ
several/JJ
decades/NNS
,/,
many/JJ
statistical/JJ
methods/NNS
have/VBP
been/VBN
developed/VBN
to/TO
detect/VB
genetic/JJ
variants/NNS
in/IN
genome-wide/JJ
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
[/(
1/CD
]/)
,/,
since/IN
high-throughput/JJ
genotyping/VBG
technologies/NNS
have/VBP
provided/VBN
a/DT
large/JJ
scale/JJ
of/IN
genetic/JJ
information/NN
,/,
such/JJ
as/IN
microarray/RB
expression/NN
data/NNS
,/,
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNP/NN
)/)
,/,
copy/NN
number/NN
variants/NNS
,/,
and/CC
so/RB
forth/IN
./.
====================
In/IN
most/JJS
early/JJ
GWASs/NNS
,/,
a/DT
single-SNP/JJ
approach/NN
was/VBD
widely/RB
used/VBN
to/TO
identify/VB
genetic/JJ
variations/NNS
associated/VBN
with/IN
common/JJ
and/CC
complex/NN
diseases/NNS
,/,
because/IN
it/PRP
is/VBZ
relatively/RB
easy/RB
and/CC
efficient/JJ
to/TO
estimate/VB
and/CC
test/VB
the/DT
effect/NN
of/IN
genetic/JJ
variants/NNS
./.
====================
However/RB
,/,
this/DT
single-SNP/JJ
approach/NN
yields/VBZ
the/DT
missing/JJ
heritability/NN
problem/NN
[/(
2/CD
]/)
,/,
because/IN
many/JJ
complex/NN
diseases/NNS
are/VBP
naturally/RB
related/JJ
to/TO
multiple/JJ
genes/NNS
and/CC
their/PRP$
interactions/NNS
,/,
rather/RB
than/IN
a/DT
single-SNP/JJ
./.
====================
Thus/RB
,/,
many/JJ
approaches/NNS
for/IN
solving/JJ
the/DT
missing/JJ
heritability/NN
problem/NN
have/VBP
been/VBN
studied/VBN
,/,
such/JJ
as/IN
meta-analysis/NN
,/,
analysis/NN
of/IN
rare/JJ
variants/NNS
from/IN
next-generation/NN
sequencing/NN
,/,
and/CC
analysis/NN
of/IN
gene-gene/NN
interactions/NNS
./.
====================
This/DT
paper/NN
focuses/VBZ
on/IN
the/DT
analysis/NN
of/IN
gene-gene/NN
interactions/NNS
associated/VBN
with/IN
the/DT
survival/NN
phenotype/NN
in/IN
prospective/JJ
studies/NNS
./.
====================
Since/IN
the/DT
analysis/NN
of/IN
gene-gene/NN
interactions/NNS
involves/VBZ
high-dimension/JJ
variables/NNS
,/,
the/DT
method/NN
for/IN
reducing/VBG
high-dimension/JJ
to/TO
lower-dimension/JJ
variables/NNS
is/VBZ
practically/RB
useful/JJ
to/TO
estimate/VB
the/DT
effects/NNS
of/IN
genes/NNS
and/CC
their/PRP$
interactions/NNS
with/IN
the/DT
appropriate/JJ
models/NNS
./.
====================
As/IN
a/DT
strategy/NN
to/TO
reduce/VB
the/DT
dimension/NN
of/IN
high-order/JJ
variables/NNS
,/,
the/DT
multifactor/JJ
dimensionality/NN
reduction/NN
(/(
MDR/NN
)/)
method/NN
has/VBZ
been/VBN
proposed/VBN
by/IN
Ritchie/NN
et/FW
al/JJ
./.
====================
[/(
3/CD
]/)
,/,
in/IN
which/WDT
multi-level/JJ
genotypes/NNS
are/VBP
efficiently/RB
reduced/VBN
into/IN
a/DT
binary/JJ
attribute/VBP
to/TO
detect/VB
non-linear/JJ
patterns/NNS
of/IN
gene-gene/NN
interactions/NNS
in/IN
GWASs/NNS
./.
====================
The/DT
MDR/NN
method/NN
originally/RB
was/VBD
proposed/VBN
for/IN
a/DT
binary/JJ
phenotype/NN
in/IN
a/DT
case-control/JJ
study/NN
,/,
and/CC
it/PRP
is/VBZ
a/DT
nonparametric/JJ
and/CC
genetic/JJ
model-free/NN
approach/NN
./.
====================
The/DT
key/JJ
idea/NN
of/IN
MDR/NN
is/VBZ
to/TO
classify/VB
multi-dimensional/JJ
genotypes/NNS
into/IN
one-dimensional/JJ
binary/NN
attributes/NNS
by/IN
pooling/VBG
genotypes/NNS
of/IN
multiple/JJ
SNPs/NNS
using/VBG
a/DT
well-defined/JJ
statistic/JJ
,/,
such/JJ
as/IN
the/DT
ratio/NN
of/IN
cases/NNS
and/CC
controls/VBZ
./.
====================
Many/JJ
modifications/NNS
for/IN
MDR/NN
have/VBP
been/VBN
proposed/VBN
by/IN
generalizing/VBG
the/DT
binary/NN
phenotype/NN
to/TO
quantitative/JJ
traits/VBZ
and/CC
survival/NN
time/NN
with/IN
various/JJ
classifiers/NNS
./.
====================
For/IN
example/NN
,/,
Lou/NNP
et/FW
al/JJ
./.
====================
[/(
4/CD
]/)
proposed/VBN
a/DT
generalized/VBN
MDR/NN
(/(
GMDR/NN
)/)
,/,
which/WDT
includes/VBZ
both/CC
binary/JJ
and/CC
continuous/JJ
phenotypes/NNS
and/CC
uses/VBZ
a/DT
score-based/VBN
residual/JJ
to/TO
classify/VB
multi-level/JJ
genotypes/NNS
into/IN
high-/JJ
and/CC
low-risk/JJ
groups/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
GMDR/NN
allows/VBZ
for/IN
the/DT
adjustment/JJ
of/IN
covariates/NNS
,/,
such/JJ
as/IN
many/JJ
demographic/JJ
variables/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
constructive/JJ
induction/NN
algorithm/NN
of/IN
MDR/NN
has/VBZ
also/RB
been/VBN
extended/VBN
to/TO
investigate/VB
gene-gene/NN
interactions/NNS
associated/VBN
with/IN
the/DT
survival/NN
phenotype/NN
./.
====================
Gui/NN
et/FW
al/JJ
./.
====================
[/(
5/CD
]/)
first/JJ
proposed/JJ
a/DT
novel/JJ
approach/NN
,/,
called/VBN
Survival-MDR/NN
(/(
Surv-MDR/NN
)/)
,/,
for/IN
detecting/VBG
gene-gene/NN
interactions/NNS
with/IN
survival/NN
times/NNS
using/VBG
the/DT
combinatorial/JJ
algorithm/NN
of/IN
MDR/NN
./.
====================
The/DT
Surv-MDR/NN
method/NN
replaces/VBZ
case-control/JJ
ratios/NNS
by/IN
a/DT
log-rank/NN
test/NN
statistic/JJ
with/IN
survival/NN
time/NN
./.
====================
Thus/RB
,/,
the/DT
balanced/JJ
accuracy/NN
is/VBZ
replaced/VBN
by/IN
a/DT
log-rank/NN
test/NN
statistic/JJ
,/,
but/CC
the/DT
other/JJ
cross-validation/NN
procedure/NN
for/IN
selecting/VBG
the/DT
best/JJS
model/NN
is/VBZ
unchanged/JJ
./.
====================
It/PRP
has/VBZ
been/VBN
shown/VBN
that/IN
Surv-MDR/NN
has/VBZ
better/RBR
power/JJR
than/IN
traditional/JJ
Cox/NN
regression/NN
models/NNS
through/IN
intensive/JJ
simulation/NN
studies/NNS
./.
====================
Also/RB
,/,
Surv-MD/NN
has/VBZ
successfully/RB
identified/VBN
the/DT
SNP-SNP/NN
interactions/NNS
associated/VBN
with/IN
survival/NN
time/NN
in/IN
bladder/JJ
cancer/NN
data/NNS
,/,
as/IN
shown/VBN
in/IN
Andrew/NN
et/FW
al/JJ
./.
====================
[/(
6/CD
]/)
./.
====================
However/RB
,/,
there/EX
exists/VBZ
a/DT
weakness/JJ
of/IN
Surv-MDR/NN
,/,
which/WDT
can/MD
not/RB
adjust/JJ
the/DT
effect/NN
of/IN
the/DT
covariate/NN
,/,
because/IN
it/PRP
uses/VBZ
the/DT
log-rank/NN
test/NN
statistic/JJ
as/IN
a/DT
classifier/NN
./.
====================
To/TO
overcome/VB
the/DT
disadvantage/JJ
of/IN
Surv-MDR/NN
,/,
Lee/NNP
et/FW
al/JJ
./.
====================
[/(
7/CD
]/)
proposed/VBN
a/DT
simple/JJ
method/NN
,/,
called/VBN
Cox-MDR/NN
,/,
which/WDT
uses/VBZ
a/DT
martingale/JJ
residual/JJ
as/IN
a/DT
classifier/NN
and/CC
allows/VBZ
for/IN
the/DT
adjustment/JJ
of/IN
covariates/NNS
./.
====================
Similarly/RB
,/,
Oh/NNP
and/CC
Lee/NNP
[/(
8/CD
]/)
proposed/VBN
another/DT
method/NN
,/,
called/VBN
AFT-MDR/NN
,/,
which/WDT
uses/VBZ
a/DT
standardized/JJ
residual/JJ
as/IN
a/DT
new/JJ
classifier/NN
./.
====================
In/IN
an/DT
accelerated/VBN
failure/NN
time/NN
model/NN
,/,
the/DT
standardized/VBN
residual/JJ
is/VBZ
the/DT
normalized/VBN
difference/NN
between/IN
the/DT
observed/VBN
log/NN
survival/NN
time/NN
and/CC
the/DT
expected/VBN
log/NN
survival/NN
time/NN
under/IN
the/DT
assumed/VBN
model/NN
./.
====================
Thus/RB
,/,
it/PRP
can/MD
be/VB
interpreted/VBN
that/IN
a/DT
positive/JJ
standardized/VBD
residual/JJ
implies/VBZ
a/DT
longer/RBR
survival/NN
effect/NN
,/,
while/IN
a/DT
negative/JJ
standardized/VBD
residual/JJ
implies/VBZ
a/DT
shorter/JJR
survival/NN
effect/NN
than/IN
expected/VBN
./.
====================
It/PRP
is/VBZ
reasonable/JJ
to/TO
classify/VB
subjects/NNS
into/IN
high-/JJ
and/CC
low-risk/JJ
groups/NNS
by/IN
the/DT
standardized/VBN
residual/JJ
,/,
since/IN
it/PRP
can/MD
be/VB
interpreted/VBN
as/IN
a/DT
measure/JJ
of/IN
association/NN
between/IN
putative/JJ
genetic/JJ
factors/NNS
and/CC
survival/NN
time/NN
./.
====================
Furthermore/RB
,/,
AFT-MDR/NN
can/MD
adjust/VB
for/IN
the/DT
effect/NN
of/IN
covariates/NNS
under/IN
the/DT
framework/NN
of/IN
the/DT
accelerated/VBN
failure/NN
time/NN
regression/NN
model/NN
,/,
unlike/IN
Surv-MDR/NN
./.
====================
However/RB
,/,
both/CC
Surv-MDR/NN
and/CC
AFT-MDR/NN
only/RB
provide/VBP
the/DT
best/JJS
pair/NN
of/IN
SNPs/NNS
,/,
which/WDT
is/VBZ
selected/VBN
by/IN
10-fold/JJ
cross-validation/NN
,/,
and/CC
the/DT
significance/NN
of/IN
a/DT
gene-gene/JJ
interaction/NN
is/VBZ
achieved/VBN
by/IN
intensive/JJ
permutations/NNS
./.
====================
Recently/RB
,/,
Yu/NNP
et/FW
al/JJ
./.
====================
[/(
9/CD
]/)
proposed/VBN
a/DT
unified/JJ
model-based/VBN
MDR/NN
(/(
UM-MDR/NN
)/)
method/NN
to/TO
overcome/VB
the/DT
disadvantage/JJ
of/IN
MDR/NN
,/,
which/WDT
needs/VBZ
permutation/NN
tests/NNS
for/IN
the/DT
significance/NN
of/IN
the/DT
effect/NN
of/IN
the/DT
best/JJS
pair/NN
of/IN
SNPs/NNS
./.
====================
The/DT
UM-MDR/NN
method/NN
includes/VBZ
two/CD
steps/NNS
for/IN
investigating/VBG
gene-gene/NN
interactions/NNS
,/,
in/IN
which/WDT
multi-dimensional/JJ
genotypes/NNS
are/VBP
classified/VBN
into/IN
high-/JJ
and/CC
low-risk/JJ
groups/NNS
,/,
and/CC
then/RB
,/,
an/DT
indicator/NN
for/IN
the/DT
high-risk/JJ
group/NN
is/VBZ
defined/VBN
in/IN
the/DT
first/JJ
step/NN
./.
====================
In/IN
the/DT
second/JJ
step/NN
of/IN
the/DT
UM-MDR/NN
method/NN
,/,
the/DT
indicator/NN
variable/JJ
for/IN
the/DT
high-risk/JJ
group/NN
is/VBZ
considered/VBN
a/DT
covariate/JJ
,/,
with/IN
other/JJ
adjusted/JJ
covariates/VBZ
in/IN
the/DT
regression/NN
model/NN
./.
====================
Then/RB
,/,
the/DT
significance/NN
of/IN
a/DT
gene-gene/JJ
interaction/NN
is/VBZ
obtained/VBN
by/IN
testing/VBG
the/DT
indicator/NN
variable/JJ
of/IN
the/DT
high-risk/JJ
group/NN
./.
====================
Through/IN
simulation/JJ
studies/NNS
,/,
we/PRP
compared/VBD
the/DT
proposed/JJ
method/NN
with/IN
AFT-MDR/NN
with/IN
and/CC
without/IN
the/DT
main/JJ
effect/NN
using/VBG
70/CD
different/JJ
penetrance/NN
models/NNS
listed/VBN
by/IN
Velez/NNP
et/FW
al/JJ
./.
====================
[/(
10/CD
]/)
./.
====================
From/IN
the/DT
simulation/JJ
results/NNS
,/,
the/DT
power/JJ
of/IN
the/DT
proposed/JJ
method/NN
is/VBZ
similar/JJ
to/TO
that/DT
of/IN
AFT-MDR/NN
when/WRB
the/DT
main/JJ
effect/NN
is/VBZ
not/RB
considered/VBN
,/,
but/CC
it/PRP
performs/VBZ
better/RBR
than/IN
AFT-MDR/NN
when/WRB
the/DT
censoring/JJ
fraction/NN
is/VBZ
greater/JJR
than/IN
0.3/CD
./.
====================
In/IN
addition/NN
,/,
the/DT
power/JJ
of/IN
the/DT
proposed/JJ
method/NN
is/VBZ
much/RB
greater/JJR
than/IN
that/DT
of/IN
AFT-MDR/NN
when/WRB
the/DT
main/JJ
effect/NN
is/VBZ
considered/VBN
,/,
while/IN
AFT-MDR/NN
has/VBZ
no/DT
power/RBR
when/WRB
there/EX
is/VBZ
a/DT
strong/JJ
main/JJ
effect/NN
./.
====================
The/DT
power/JJR
of/IN
the/DT
proposed/JJ
method/NN
also/RB
decreases/VBZ
as/IN
the/DT
censoring/JJ
fraction/NN
increases/VBZ
./.
====================
Let/NNP
Ti/NNP
denote/VBP
the/DT
survival/NN
time/NN
for/IN
the/DT
ith/IN
individual/JJ
and/CC
xi/FW
and/CC
zi/NN
denote/VBP
the/DT
predictor/NN
variable/JJ
vector/NN
coding/VBG
a/DT
gene-gene/JJ
and/CC
gene-environment/JJ
interaction/NN
of/IN
interest/NN
and/CC
the/DT
vector/NN
coding/VBG
for/IN
the/DT
covariates/NNS
,/,
respectively/RB
./.
====================
Let/NN
β/NN
and/CC
γ/JJ
be/VB
the/DT
corresponding/JJ
parameter/NN
vectors/NNS
to/TO
xi/VB
and/CC
zi/NN
,/,
respectively/RB
./.
====================
Then/RB
,/,
we/PRP
call/JJ
β/NN
the/DT
target/NN
effects/NNS
and/CC
γ/JJ
the/DT
covariate/NN
effects/NNS
./.
====================
The/DT
parametric/JJ
regression/NN
model/NN
represents/VBZ
the/DT
linear/JJ
relationship/NN
between/IN
the/DT
log/NN
survival/NN
time/NN
and/CC
covariates/VBZ
as/IN
follows/VBZ
:/:
Y/NN
=/JJ
logT/NN
=/JJ
µ/CD
+/JJ
β/RB
'/``
X/NN
+/JJ
γ/RB
'/``
Z/NN
+/JJ
σW/NN
./.
====================
Here/RB
,/,
µ/RB
is/VBZ
the/DT
mean/JJ
value/NN
of/IN
the/DT
log/NN
survival/NN
time/NN
when/WRB
X/NN
=/JJ
Z/NN
=/JJ
0/CD
,/,
σ/RB
is/VBZ
a/DT
scale/JJ
parameter/NN
,/,
and/CC
W/NN
is/VBZ
the/DT
error/NN
distribution/NN
./.
====================
When/WRB
T/NN
has/VBZ
a/DT
Weibull/JJ
distribution/NN
,/,
W/NN
has/VBZ
a/DT
standard/JJ
extreme/JJ
value/NN
distribution/NN
./.
====================
For/IN
a/DT
log-logistic/JJ
distribution/NN
,/,
W/NN
has/VBZ
a/DT
standard/JJ
logistic/JJ
distribution/NN
./.
====================
The/DT
standardized/VBN
residual/JJ
for/IN
the/DT
ith/IN
individual/JJ
,/,
si=logTiμ^Y^′Ziσ^/JJ
,/,
is/VBZ
obtained/VBN
from/IN
the/DT
null/JJ
model/NN
of/IN
no/DT
target/NN
effects/NNS
(/(
i.e./FW
,/,
β/RB
=/JJ
0/CD
)/)
./.
====================
Since/IN
the/DT
standardized/VBN
residual/JJ
is/VBZ
the/DT
difference/NN
between/IN
the/DT
observed/VBN
and/CC
expected/VBN
survival/NN
time/NN
under/IN
the/DT
null/JJ
model/NN
with/IN
no/DT
SNP/NN
effects/NNS
,/,
the/DT
magnitude/NN
and/CC
sign/NN
of/IN
the/DT
standardized/VBN
residual/JJ
provide/VBP
a/DT
measure/JJ
of/IN
the/DT
association/NN
between/IN
SNPs/NNS
and/CC
survival/NN
time/NN
./.
====================
Those/DT
patients/NNS
who/WP
have/VBP
positive/JJ
standardized/VBD
residuals/NNS
are/VBP
at/IN
low/JJ
risk/NN
for/IN
the/DT
disease/NN
,/,
because/IN
one/CD
survives/VBZ
longer/RBR
than/IN
expected/VBN
under/IN
the/DT
null/JJ
model/NN
./.
====================
Similarly/RB
,/,
those/DT
patients/NNS
who/WP
have/VBP
negative/JJ
standardized/VBD
residuals/NNS
are/VBP
at/IN
high/JJ
risk/NN
for/IN
the/DT
disease/NN
,/,
because/IN
one/CD
dies/VBZ
earlier/RBR
than/IN
expected/VBN
./.
====================
Thus/RB
,/,
each/DT
individual/JJ
with/IN
a/DT
positive/JJ
standardized/VBD
residual/JJ
is/VBZ
classified/VBN
as/IN
a/DT
control/JJ
,/,
whereas/IN
one/CD
with/IN
a/DT
negative/JJ
standardized/VBD
residual/JJ
is/VBZ
classified/VBN
as/IN
a/DT
case/NN
./.
====================
In/IN
addition/NN
,/,
for/IN
each/DT
multi-locus/JJ
genotype/NN
combination/NN
of/IN
SNPs/NNS
,/,
we/PRP
calculate/VBP
the/DT
sum/NN
of/IN
the/DT
standardized/VBN
residuals/NNS
of/IN
those/DT
patients/NNS
who/WP
have/VBP
the/DT
corresponding/JJ
genotype/NN
and/CC
replace/NN
the/DT
case-control/JJ
ratios/NNS
with/IN
the/DT
sum/NN
of/IN
the/DT
standardized/VBN
residual/JJ
to/TO
discriminate/VB
between/IN
high-/JJ
and/CC
low-risk/JJ
groups/NNS
./.
====================
We/PRP
assign/VBP
the/DT
cell/NN
as/IN
low-risk/JJ
if/IN
the/DT
sum/NN
of/IN
standardized/VBN
residuals/NNS
within/IN
that/DT
cell/NN
is/VBZ
greater/JJR
than/IN
or/CC
equal/JJ
to/TO
0/CD
and/CC
as/IN
high-risk/JJ
otherwise/RB
./.
====================
The/DT
process/NN
of/IN
AFT-MDR/NN
is/VBZ
done/VBN
by/IN
following/VBG
the/DT
algorithm/NN
of/IN
the/DT
original/JJ
MDR/NN
through/IN
10-fold/JJ
cross-validation/NN
to/TO
select/VB
the/DT
best/JJS
pair/NN
of/IN
SNPs/NNS
./.
====================
We/PRP
propose/VBP
to/TO
improve/VB
the/DT
process/NN
of/IN
AFT-MDR/NN
by/IN
combining/VBG
the/DT
unified/JJ
model-based/VBN
MDR/NN
to/TO
test/VB
the/DT
significance/NN
of/IN
gene-gene/NN
interactions/NNS
./.
====================
In/IN
the/DT
first/JJ
step/NN
of/IN
the/DT
proposed/JJ
method/NN
,/,
multi-level/JJ
genotypes/NNS
are/VBP
classified/VBN
into/IN
high-risk/JJ
and/CC
low-risk/JJ
groups/NNS
,/,
as/IN
done/VBN
in/IN
AFT-MDR/NN
./.
====================
Then/RB
,/,
we/PRP
define/VBP
an/DT
indictor/NN
variable/JJ
,/,
S/NN
,/,
as/IN
1/CD
for/IN
the/DT
high-risk/JJ
group/NN
and/CC
0/CD
otherwise/RB
./.
====================
In/IN
the/DT
second/JJ
step/NN
,/,
the/DT
variable/JJ
S/NN
is/VBZ
considered/VBN
with/IN
the/DT
other/JJ
adjusting/JJ
covariates/VBZ
in/IN
the/DT
accelerated/VBN
failure/NN
time/NN
regression/NN
model/NN
./.
====================
The/DT
testing/NN
for/IN
the/DT
significance/NN
of/IN
S/NN
implies/VBZ
that/IN
there/EX
is/VBZ
a/DT
significant/JJ
gene-gene/NN
interaction/NN
associated/VBN
with/IN
survival/NN
time/NN
./.
====================
For/IN
testing/NN
the/DT
significance/NN
of/IN
S/NN
,/,
a/DT
Wald-type/JJ
test/NN
statistic/JJ
is/VBZ
used/VBN
,/,
and/CC
its/PRP$
asymptotic/JJ
distribution/NN
is/VBZ
a/DT
chi-square/JJ
distribution/NN
under/IN
the/DT
null/JJ
hypothesis/NN
of/IN
no/DT
gene-gene/NN
interaction/NN
./.
====================
However/RB
,/,
as/IN
described/VBN
in/IN
Yu/NN
et/FW
al/JJ
./.
====================
[/(
9/CD
]/)
,/,
the/DT
asymptotic/JJ
distribution/NN
of/IN
the/DT
Wald-type/JJ
test/NN
statistic/JJ
is/VBZ
not/RB
a/DT
central/JJ
chi-square/NN
distribution/NN
,/,
because/IN
the/DT
expectation/NN
of/IN
the/DT
test/NN
statistic/JJ
is/VBZ
not/RB
0/CD
under/IN
the/DT
null/JJ
hypothesis/NN
./.
====================
To/TO
adjust/VB
for/IN
the/DT
bias/NNS
of/IN
the/DT
test/NN
statistic/JJ
,/,
non-centrality/NN
is/VBZ
estimated/VBN
by/IN
a/DT
small/JJ
number/NN
of/IN
permutations—say/NN
,/,
5/CD
or/CC
10/CD
times/NNS
./.
====================
Based/VBN
on/IN
the/DT
non-central/JJ
chi-square/NN
test/NN
statistic/JJ
,/,
the/DT
significance/NN
of/IN
a/DT
gene-gene/JJ
interaction/NN
can/MD
be/VB
tested/VBN
for/IN
all/DT
possible/JJ
pairs/NNS
of/IN
SNPs/NNS
without/IN
any/DT
intensive/JJ
permutations/NNS
./.
====================
The/DT
proposed/JJ
method/NN
easily/RB
tests/NNS
the/DT
significance/NN
of/IN
a/DT
gene-gene/JJ
interaction/NN
for/IN
all/DT
possible/JJ
higher-order/JJ
pairs/NNS
of/IN
SNPs/NNS
in/IN
the/DT
framework/NN
of/IN
a/DT
regression/NN
model/NN
./.
====================
It/PRP
allows/VBZ
for/IN
the/DT
adjustment/JJ
of/IN
covariates/NNS
and/CC
the/DT
main/JJ
effect/NN
of/IN
SNPs/NNS
,/,
while/IN
the/DT
original/JJ
MDR/NN
method/NN
can/MD
not/RB
./.
====================
A/DT
simulation/JJ
study/NN
was/VBD
performed/VBN
to/TO
compare/VB
the/DT
power/JJ
of/IN
the/DT
proposed/JJ
method/NN
with/IN
that/DT
of/IN
AFT-MDR/NN
in/IN
the/DT
setting/VBG
constructed/VBN
similarly/RB
to/TO
that/DT
of/IN
Oh/JJ
and/CC
Lee/NNP
[/(
8/CD
]/)
./.
====================
We/PRP
consider/VBP
two/CD
disease-causal/JJ
SNPs/NNS
among/IN
10/CD
unlinked/JJ
diallelic/JJ
loci/NNS
with/IN
the/DT
assumption/NN
of/IN
Hardy-Weinberg/JJ
equilibrium/NN
and/CC
linkage/NN
equilibrium/NN
./.
====================
For/IN
the/DT
simulation/JJ
study/NN
,/,
survival/NN
time/NN
is/VBZ
generated/VBN
from/IN
an/DT
accelerated/VBN
regression/NN
model/NN
as/IN
follows/VBZ
:/:
log/NN
(/(
T/NN
)/)
=/JJ
µ/RB
+/CC
βfij/RB
+/CC
γZ/JJ
+/CC
σW/NN
,/,
where/WRB
fij/JJ
=/JJ
P/NN
(/(
high/JJ
risk|SNP1/NN
=/JJ
i/LS
,/,
SNP2/NN
=/JJ
j/RB
)/)
,/,
Z~N/NNP
(/(
0,1/CD
)/)
,/,
W~N/NNP
(/(
0,1/CD
)/)
./.
====================
Here/RB
,/,
fij/RB
is/VBZ
an/DT
element/NN
from/IN
the/DT
ith/IN
row/NN
and/CC
the/DT
jth/NN
column/NN
of/IN
a/DT
penetrance/NN
function/NN
,/,
which/WDT
defines/VBZ
a/DT
probabilistic/JJ
relationship/NN
between/IN
a/DT
status/NN
of/IN
high-risk/JJ
or/CC
low-risk/JJ
and/CC
SNPs/NNS
./.
====================
We/PRP
consider/VBP
14/CD
different/JJ
combinations/NNS
of/IN
two/CD
different/JJ
minor/JJ
allele/NN
frequencies/NNS
of/IN
(/(
0.2/CD
and/CC
0.4/CD
)/)
and/CC
seven/CD
different/JJ
heritabilities/NNS
of/IN
(/(
0.01/CD
,/,
0.025/CD
,/,
0.05/CD
,/,
0.1/CD
,/,
0.2/CD
,/,
0.3/CD
,/,
and/CC
0.4/CD
)/)
and/CC
70/CD
epistatic/JJ
models/NNS
with/IN
70/CD
various/JJ
penetrance/NN
functions/NNS
,/,
as/IN
described/VBN
by/IN
Velez/NNP
et/FW
al/JJ
./.
====================
[/(
10/CD
]/)
./.
====================
We/PRP
also/RB
consider/VBP
four/CD
censoring/JJ
fractions/NNS
(/(
0.0/CD
,/,
0.1/CD
,/,
0.3/CD
,/,
and/CC
0.5/CD
)/)
./.
====================
We/PRP
generate/VBP
200/CD
high-risk/VBP
patients/NNS
and/CC
200/CD
low-risk/NN
patients/NNS
from/IN
each/DT
of/IN
the/DT
70/CD
penetrance/NN
models/NNS
to/TO
create/VB
one/CD
simulated/JJ
dataset/NN
,/,
and/CC
we/PRP
generate/VBP
100/CD
datasets/NNS
for/IN
each/DT
model/NN
./.
====================
We/PRP
set/VBP
µ/RB
=/JJ
0.0/CD
,/,
β/RB
=/JJ
−1.0/CD
,/,
γ/RB
=/JJ
1.0/CD
,/,
σ/RB
=/JJ
1.0/CD
./.
====================
First/RB
,/,
we/PRP
check/VBP
whether/IN
or/CC
not/RB
a/DT
type-I/JJ
error/NN
is/VBZ
well/RB
preserved/VBN
under/IN
the/DT
null/JJ
hypothesis/NN
./.
====================
As/IN
shown/VBN
in/IN
Table/JJ
1/CD
and/CC
Fig/NN
./.
====================
1/CD
,/,
there/EX
are/VBP
two/CD
kinds/NNS
of/IN
type-I/JJ
errors/NNS
:/:
uncorrected/JJ
and/CC
corrected/VBD
./.
====================
The/DT
uncorrected/JJ
type-I/JJ
error/NN
is/VBZ
obtained/VBN
from/IN
the/DT
asymptotic/JJ
central/JJ
chi-square/NN
distribution/NN
,/,
whereas/IN
the/DT
corrected/JJ
type-I/JJ
error/NN
is/VBZ
calculated/VBN
from/IN
the/DT
non-central/JJ
chi-square/NN
distribution/NN
./.
====================
For/IN
the/DT
non-centrality/NN
parameter/NN
,/,
5/CD
or/CC
10/CD
permutations/NNS
are/VBP
performed/VBN
when/WRB
the/DT
censoring/JJ
fraction/NN
is/VBZ
less/RBR
than/IN
0.3/CD
,/,
but/CC
30/CD
permutations/NNS
are/VBP
needed/VBN
to/TO
estimate/VB
the/DT
non-centrality/NN
under/IN
censoring/JJ
heavier/NN
than/IN
0.3/CD
./.
====================
The/DT
results/NNS
of/IN
Table/JJ
1/CD
show/VBP
that/IN
the/DT
type-I/JJ
error/NN
is/VBZ
well/RB
controlled/VBN
over/IN
all/DT
combinations/NNS
of/IN
minor/JJ
allele/NN
frequencies/NNS
and/CC
censoring/JJ
fractions/NNS
./.
====================
Fig/NN
./.
====================
1/CD
displays/VBZ
the/DT
result/NN
of/IN
Table/JJ
1/CD
./.
====================
For/IN
the/DT
comparison/NN
of/IN
power/JJR
,/,
we/PRP
define/VBP
two/CD
powers/NNS
,/,
PBonf/NN
and/CC
PRank/NN
./.
====================
PBonf/NN
is/VBZ
the/DT
proportion/NN
of/IN
p-values/NNS
less/RBR
than/IN
the/DT
nominal/JJ
sizes/NNS
after/IN
adjusting/VBG
for/IN
multiple/JJ
testing/VBG
among/IN
100/CD
cases/NNS
./.
====================
However/RB
,/,
the/DT
power/JJ
of/IN
AFT-MDR/NN
is/VBZ
defined/VBN
as/IN
the/DT
percentage/NN
of/IN
times/NNS
that/DT
it/PRP
correctly/RB
chooses/NNS
the/DT
disease-causal/JJ
model/NN
out/RP
of/IN
each/DT
set/NN
of/IN
100/CD
datasets/NNS
./.
====================
Thus/RB
,/,
we/PRP
comparably/RB
define/VBP
the/DT
power/JJ
of/IN
the/DT
proposed/JJ
method/NN
as/IN
PRank/NN
,/,
which/WDT
is/VBZ
estimated/VBN
as/IN
the/DT
percentage/NN
of/IN
times/NNS
that/DT
the/DT
causal/JJ
model/NN
has/VBZ
the/DT
smallest/JJS
p-value/NN
out/IN
of/IN
all/DT
possible/JJ
multi-locus/JJ
models/NNS
./.
====================
We/PRP
compared/VBD
these/DT
three/CD
powers/NNS
in/IN
the/DT
simulation/JJ
study/NN
./.
====================
In/IN
addition/NN
,/,
we/PRP
simulated/VBD
two/CD
different/JJ
scenarios/NNS
according/VBG
to/TO
the/DT
main/JJ
effect/NN
./.
====================
In/IN
the/DT
first/JJ
scenario/NN
,/,
we/PRP
consider/VBP
the/DT
model/NN
without/IN
any/DT
main/JJ
effect/NN
of/IN
SNPs/NNS
;/:
Fig/NN
./.
====================
2/CD
and/CC
Table/JJ
2/CD
display/VBP
the/DT
power/JJ
of/IN
the/DT
PBonf/NN
,/,
PRank/NN
,/,
and/CC
AFT-MDR/NN
methods/NNS
over/IN
various/JJ
combinations/NNS
of/IN
two/CD
different/JJ
minor/JJ
allele/NN
frequencies/NNS
,/,
seven/CD
different/JJ
heritabilities/NNS
,/,
and/CC
four/CD
different/JJ
censoring/JJ
fractions/NNS
./.
====================
As/IN
indicated/VBD
in/IN
Fig/NN
./.
====================
2/CD
,/,
PRank/NN
is/VBZ
greater/JJR
than/IN
PBonf/NN
and/CC
the/DT
power/JJ
of/IN
AFT-MDR/NN
for/IN
all/DT
cases/NNS
,/,
whereas/IN
the/DT
power/JJ
of/IN
AFT-MDR/NN
is/VBZ
less/RBR
than/IN
PBonf/NN
,/,
although/IN
the/DT
difference/NN
is/VBZ
smaller/JJR
,/,
as/IN
the/DT
censoring/JJ
fraction/NN
is/VBZ
larger/RBR
than/IN
0.5/CD
./.
====================
The/DT
trend/NN
of/IN
these/DT
three/CD
powers/NNS
is/VBZ
similar/JJ
,/,
in/IN
the/DT
sense/NN
that/DT
they/PRP
increase/VBP
as/IN
the/DT
heritability/NN
increases/VBZ
,/,
whereas/IN
they/PRP
decrease/VBP
as/IN
the/DT
censoring/JJ
fraction/NN
increases/VBZ
./.
====================
In/IN
addition/NN
,/,
it/PRP
is/VBZ
shown/VBN
that/IN
the/DT
power/JJ
is/VBZ
relatively/RB
larger/JJR
when/WRB
the/DT
minor/JJ
allele/NN
frequency/NN
(/(
MAF/NN
)/)
is/VBZ
0.2/CD
than/IN
when/WRB
the/DT
MAF/NN
is/VBZ
0.4/CD
./.
====================
When/WRB
the/DT
heritability/NN
is/VBZ
smaller/JJR
than/IN
0.1/CD
,/,
the/DT
power/JJ
is/VBZ
not/RB
larger/RBR
than/IN
0.3/CD
,/,
but/CC
PRank/NN
rapidly/RB
increases/VBZ
as/IN
the/DT
heritability/NN
is/VBZ
greater/JJR
than/IN
0.1/CD
,/,
but/CC
both/CC
PBonf/JJ
and/CC
the/DT
power/JJ
of/IN
AFT-MDR/NN
slowly/RB
increase/VBP
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
in/IN
the/DT
second/JJ
scenario/NN
,/,
we/PRP
generated/VBD
the/DT
survival/NN
time/NN
by/IN
considering/VBG
the/DT
main/JJ
effect/NN
of/IN
SNP3/NN
as/IN
follows/VBZ
:/:
log/NN
(/(
T/NN
)/)
=/JJ
µ/RB
+/JJ
βfij/RB
+/JJ
γZ/JJ
+/JJ
αSNP3/NN
+/JJ
σW/NN
./.
====================
After/IN
classifying/VBG
the/DT
high-risk/JJ
and/CC
low-risk/JJ
groups/NNS
by/IN
the/DT
standardized/VBN
residual/JJ
,/,
as/IN
done/RB
in/IN
AFT-MDR/NN
,/,
the/DT
indicator/NN
variable/JJ
for/IN
the/DT
high-risk/JJ
group/NN
,/,
S/NN
,/,
is/VBZ
defined/VBN
,/,
and/CC
the/DT
significance/NN
of/IN
the/DT
gene-gene/JJ
interactions/NNS
between/IN
SNP1/NN
and/CC
SNP2/NN
is/VBZ
tested/VBN
under/IN
the/DT
following/VBG
model/NN
:/:
log/NN
(/(
T/NN
)/)
=/JJ
µ/RB
+/CC
β1SNP1/NN
+/CC
β2SNP2/NN
+/CC
δS/NNS
+/CC
γZ/JJ
+/CC
σW/NN
./.
====================
From/IN
the/DT
simulation/JJ
results/NNS
,/,
the/DT
power/NN
of/IN
PBonf/NN
,/,
PRank/NN
,/,
and/CC
AFT-MDR/NN
is/VBZ
similarly/RB
obtained/VBN
and/CC
displayed/VBD
in/IN
Fig/NN
./.
====================
3/CD
and/CC
Table/JJ
3/CD
./.
====================
As/IN
shown/VBN
in/IN
Fig/NN
./.
====================
3/CD
,/,
the/DT
power/JJ
of/IN
AFT-MDR/NN
is/VBZ
almost/RB
0/CD
for/IN
all/DT
cases/NNS
,/,
whereas/IN
PRank/NN
shows/VBZ
a/DT
similar/JJ
trend/NN
,/,
as/IN
shown/VBN
in/IN
Fig/NN
./.
====================
2/CD
,/,
when/WRB
the/DT
main/JJ
effect/NN
is/VBZ
not/RB
considered/VBN
./.
====================
However/RB
,/,
the/DT
size/NN
of/IN
PBonf/NN
is/VBZ
also/RB
smaller/JJR
,/,
as/IN
shown/VBN
in/IN
Fig/NN
./.
====================
2/CD
,/,
and/CC
has/VBZ
almost/RB
no/DT
power/JJ
when/WRB
the/DT
MAF/NN
is/VBZ
0.4/CD
and/CC
censoring/JJ
fraction/NN
is/VBZ
larger/JJR
than/IN
0.1/CD
./.
====================
The/DT
effect/NN
of/IN
the/DT
censoring/JJ
fraction/NN
is/VBZ
much/RB
larger/JJR
on/IN
these/DT
three/CD
powers/NNS
when/WRB
the/DT
main/JJ
effect/NN
is/VBZ
considered/VBN
./.
====================
Comparing/VBG
PRank/NN
with/IN
the/DT
power/JJ
of/IN
AFT-MDR/NN
,/,
AFT-MDR/NN
hardly/RB
detects/VBZ
any/DT
interaction/NN
effect/NN
when/WRB
the/DT
main/JJ
effect/NN
of/IN
SNPs/NNS
is/VBZ
considered/VBN
in/IN
the/DT
model/NN
./.
====================
However/RB
,/,
PRank/NN
has/VBZ
slightly/RB
moderate/JJ
power/JJR
when/WRB
MAF/NN
is/VBZ
0.2/CD
and/CC
the/DT
censoring/JJ
fraction/NN
is/VBZ
smaller/JJR
than/IN
0.5/CD
./.
====================
In/IN
this/DT
study/NN
,/,
the/DT
AFT/NN
UM-MDR/NN
method/NN
was/VBD
proposed/VBN
by/IN
extending/VBG
the/DT
UM-MDR/NN
method/NN
to/TO
the/DT
survival/NN
phenotype/NN
./.
====================
In/IN
the/DT
first/JJ
step/NN
,/,
the/DT
standardized/VBN
residual/JJ
of/IN
the/DT
accelerated/VBN
failure/NN
time/NN
model/NN
is/VBZ
used/VBN
to/TO
classify/VB
the/DT
multi-level/JJ
genotypes/NNS
into/IN
high-risk/JJ
and/CC
low-risk/JJ
,/,
as/IN
done/RB
in/IN
AFT-MDR/NN
,/,
and/CC
a/DT
binary/JJ
variable/JJ
is/VBZ
defined/VBN
for/IN
indicating/VBG
the/DT
high-risk/JJ
group/NN
./.
====================
Then/RB
,/,
in/IN
the/DT
second/JJ
step/NN
,/,
the/DT
significance/NN
test/NN
for/IN
an/DT
indicator/NN
for/IN
the/DT
high-risk/JJ
group/NN
,/,
defined/VBN
in/IN
the/DT
first/JJ
step/NN
,/,
is/VBZ
conducted/VBN
in/IN
the/DT
framework/NN
of/IN
the/DT
regression/NN
model/NN
,/,
as/IN
done/RB
in/IN
UM-MDR/NN
./.
====================
The/DT
big/NN
advantage/NN
of/IN
the/DT
proposed/JJ
method/NN
over/IN
AFT-MDR/NN
is/VBZ
that/DT
it/PRP
can/MD
test/VB
the/DT
significance/NN
of/IN
gene-gene/NN
interactions/NNS
without/IN
intensive/JJ
permutation/NN
procedures/NNS
./.
====================
Thus/RB
,/,
the/DT
computing/VBG
time/NN
is/VBZ
substantially/RB
reduced/VBD
,/,
and/CC
it/PRP
is/VBZ
also/RB
flexible/JJ
enough/IN
to/TO
consider/VB
the/DT
main/JJ
genetic/JJ
effect/NN
,/,
as/IN
well/RB
as/IN
gene-gene/JJ
interactions/NNS
,/,
in/IN
a/DT
model/NN
./.
====================
Throughout/RB
the/DT
simulation/JJ
studies/NNS
,/,
it/PRP
is/VBZ
shown/VBN
that/IN
the/DT
proposed/JJ
method/NN
performs/NNS
better/RBR
than/IN
AFT-MDR/NN
for/IN
both/DT
with/IN
and/CC
without/IN
the/DT
main/JJ
effect/NN
./.
====================
These/DT
powers/NNS
tend/NN
to/TO
increase/VB
as/IN
the/DT
heritability/NN
increases/VBZ
but/CC
decrease/VBP
as/IN
MAF/NN
changes/NNS
from/IN
0.2/CD
to/TO
0.4/CD
and/CC
the/DT
censoring/JJ
fraction/NN
increases/VBZ
./.
====================
Especially/RB
,/,
the/DT
power/JJ
of/IN
AFT-MDR/NN
is/VBZ
almost/RB
0/CD
under/IN
a/DT
model/NN
with/IN
a/DT
main/JJ
effect/NN
,/,
which/WDT
implies/VBZ
that/IN
the/DT
gene-gene/NN
interaction/NN
can/MD
not/RB
be/VB
detected/VBN
by/IN
AFT-MDR/NN
when/WRB
any/DT
main/JJ
genetic/JJ
effect/NN
exists/VBZ
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
the/DT
proposed/JJ
method/NN
still/RB
detects/VBZ
gene-gene/NN
interactions/NNS
,/,
even/RB
when/WRB
there/EX
is/VBZ
any/DT
main/JJ
genetic/JJ
effect/NN
./.
====================
Interestingly/RB
,/,
the/DT
censoring/JJ
fraction/NN
critically/RB
affects/VBZ
the/DT
power/JJ
when/WRB
the/DT
main/JJ
effect/NN
is/VBZ
considered/VBN
,/,
because/IN
the/DT
trend/NN
of/IN
the/DT
three/CD
powers/NNS
seems/VBZ
to/TO
be/VB
robust/JJ
over/IN
the/DT
censoring/JJ
fraction/NN
when/WRB
the/DT
main/JJ
effect/NN
is/VBZ
not/RB
considered/VBN
,/,
as/IN
shown/VBN
in/IN
Fig/NN
./.
====================
2/CD
./.
====================
As/IN
mentioned/VBN
in/IN
Yu/NN
et/FW
al/JJ
./.
====================
[/(
9/CD
]/)
,/,
the/DT
UM-MDR/NN
is/VBZ
very/RB
flexible/JJ
in/IN
the/DT
sense/NN
that/DT
various/JJ
classification/NN
rules/NNS
can/MD
be/VB
applied/VBN
./.
====================
We/PRP
have/VBP
an/DT
ongoing/JJ
study/NN
in/IN
extending/VBG
the/DT
UM-MDR/NN
to/TO
the/DT
Cox/NN
model/NN
,/,
in/IN
which/WDT
the/DT
martingale/JJ
residual/JJ
of/IN
a/DT
Cox/NN
model/NN
is/VBZ
used/VBN
as/IN
a/DT
classification/NN
rule/JJ
,/,
as/IN
done/VBN
in/IN
Cox-MDR/NN
./.
====================
Quantile-Quantile/JJ
Plot/NN
of/IN
type-I/JJ
errors/NNS
for/IN
two/CD
cases/NNS
when/WRB
the/DT
non-centrality/NN
of/IN
the/DT
chi-square/NN
distribution/NN
is/VBZ
uncorrected/JJ
and/CC
corrected/VBD
./.
====================
The/DT
power/JJR
of/IN
PBonf/JJ
,/,
PRank/NN
,/,
and/CC
AFT-MDR/NN
over/IN
the/DT
combinations/NNS
of/IN
MAF/NN
(/(
0.2/CD
and/CC
0.4/CD
)/)
,/,
heritability/RB
(/(
0.01/CD
,/,
0.025/CD
,/,
0.05/CD
,/,
0.1/CD
,/,
0.2/CD
,/,
0.3/CD
,/,
and/CC
0.4/CD
)/)
,/,
and/CC
Cf/JJ
(/(
0.0/CD
,/,
0.1/CD
,/,
0.3/CD
,/,
and/CC
0.5/CD
)/)
./.
====================
AFT-MDR/NN
,/,
accelerated/VBN
failure/NN
time/NN
multifactor/JJ
dimensionality/NN
reduction/NN
;/:
MAF/NN
,/,
minor/JJ
allele/NN
frequency/NN
;/:
Cf/NNP
,/,
censoring/VBG
fraction/NN
./.
====================
The/DT
power/JJR
of/IN
PBonf/JJ
,/,
PRank/NN
,/,
and/CC
AFT-MDR/NN
over/IN
the/DT
combinations/NNS
of/IN
MAF/NN
(/(
0.2/CD
and/CC
0.4/CD
)/)
,/,
heritability/RB
(/(
0.01/CD
,/,
0.025/CD
,/,
0.05/CD
,/,
0.1/CD
,/,
0.2/CD
,/,
0.3/CD
,/,
and/CC
0.4/CD
)/)
,/,
and/CC
Cf/JJ
(/(
0.0/CD
,/,
0.1/CD
,/,
0.3/CD
,/,
and/CC
0.5/CD
)/)
./.
====================
AFT-MDR/NN
,/,
accelerated/VBN
failure/NN
time/NN
multifactor/JJ
dimensionality/NN
reduction/NN
;/:
MAF/NN
,/,
minor/JJ
allele/NN
frequency/NN
;/:
Cf/NNP
,/,
censoring/VBG
fraction/NN
./.
====================
Type-I/NN
errors/NNS
of/IN
the/DT
proposed/JJ
method/NN
for/IN
two/CD
cases/NNS
when/WRB
the/DT
non-centrality/NN
of/IN
the/DT
chi-square/NN
distribution/NN
is/VBZ
uncorrected/JJ
and/CC
corrected/VBD
====================
The/DT
power/JJR
of/IN
PBonf/NN
,/,
PRank/NN
,/,
and/CC
AFT-MDR/NN
over/IN
the/DT
combinations/NNS
of/IN
MAF/NN
,/,
heritability/NN
,/,
and/CC
Cf/NN
====================
The/DT
power/JJR
of/IN
PBonf/NN
,/,
Prank/NN
,/,
and/CC
AFT-MDR/NN
over/IN
the/DT
combinations/NNS
of/IN
MAF/NN
,/,
heritability/NN
,/,
and/CC
Cf/NN
====================
